Clinical outcomes according to ethnicity in patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT).

被引：0
作者：
Bosse, Dominick
Xie, Wanling
Wells, Connor
Lalani, Aly-Khan A.
Donskov, Frede
Bent, Alisha
Sim, Hao-Wen
Beuselinck, Benoit
Bamias, Aristotelis
Porta, Camillo
Vaishampayan, Ulka N.
Pal, Sumanta K.
Agarwal, Neeraj
Srinivas, Sandy
Rini, Brian I.
Alva, Ajjai Shivaram
Wood, Lori
Kapoor, Anil
Choueiri, Toni K.
Heng, Daniel Yick Chin
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
[2] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA
[3] Tom Baker Canc Clin, Calgary, AB, Canada
[4] Aarhus Univ Hosp, Aarhus, Denmark
[5] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX USA
[6] Peter MacCallum Canc Ctr, Melbourne, Australia
[7] Univ Hosp Leuven, Dept Gen Med Oncol, Leuven Canc Inst, KU Leuven, Leuven, Belgium
[8] Univ Athens, Dept Clin Therapeut, Athens, Greece
[9] IRCCS San Matteo Univ Hosp Fdn, Padua, Italy
[10] Karmanos Canc Inst, Detroit, MI USA
[11] City Hope Natl Med Ctr, Comprehens Canc Ctr, Duarte, CA USA
[12] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[13] Stanford Univ, Stanford, CA USA
[14] Cleveland Clin, Taussig Canc Insitute, Cleveland, OH USA
[15] Univ Michigan, Div Hematol Oncol, Dept Internal Med, Ann Arbor, MI USA
[16] QEII Hlth Sci Ctr, Halifax, NS, Canada
[17] McMaster Univ, Juravinski Canc Ctr, Hamilton, ON, Canada
[18] Brigham & Womens Hosp, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e16065
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16065
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies
    Gruenwald, V.
    Seidel, C.
    Fenner, M.
    Ganser, A.
    Busch, J.
    Weikert, S.
    BRITISH JOURNAL OF CANCER, 2011, 105 (11) : 1635 - 1639
  • [42] Progression-free survival (PFS) of first-line VEGF-targeted therapy as a prognostic parameter for overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).
    Seidel, C.
    Fenner, M.
    Reuter, C. W.
    Ganser, A.
    Gruenwald, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [43] Characteristics of metastatic renal cell carcinoma (mRCC) patients treated with delayed targeted therapy: Results from the International mRCC Consortium (IMDC).
    Li, Haoran
    Choueiri, Toni K.
    Wells, Connor
    Agarwal, Neeraj
    Donskov, Frede
    Lee, Jae-Lyun
    Broom, Reuben James
    Yuasa, Takeshi
    Rini, Brian I.
    Pal, Sumanta Kumar
    Wood, Lori
    Ernst, D. Scott
    Kollmannsberger, Christian K.
    Vaishampayan, Ulka N.
    Rha, Sun Young
    Bjarnason, Georg A.
    Knox, Jennifer J.
    Saleem, Sadia
    Beuselinck, Benoit
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [44] Prognostic biomarkers for patients with advanced renal cell carcinoma treated with VEGF-targeted tyrosine kinase inhibitors
    Cho, Daniel C.
    ONCOTARGETS AND THERAPY, 2013, 6 : 679 - 684
  • [45] Gender as a factor associated with poor compliance in the treatment of metastatic renal cell carcinoma with VEGF-targeted therapy in Japanese patients.
    Uemura, Motohide
    Tsujimura, Akira
    Kawashima, Atsunari
    Arai, Yasuyuki
    Tanigawa, Go
    Nin, Mikio
    Yasunaga, Yutaka
    Yoshioka, Toshiaki
    Nomura, Hironori
    Mukai, Masatoshi
    Fukuda, Satoko
    Oka, Daizo
    Nishimura, Kenji
    Yoshida, Takahiro
    Satou, Mototaka
    Hatano, Koji
    Nakai, Yasutomo
    Takayama, Hitoshi
    Nishimura, Kazuo
    Nonomura, Norio
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [46] Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies
    V Grünwald
    C Seidel
    M Fenner
    A Ganser
    J Busch
    S Weikert
    British Journal of Cancer, 2011, 105 : 1635 - 1639
  • [47] Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma
    De Velasco, Guillermo
    Xie, Wanling
    Donskov, Frede
    Albiges, Laurence
    Beuselinck, Benoit
    Srinivas, Sandy
    Agarwal, Neeraj
    Lee, Jae Lyun
    Brugarolas, James
    Wood, Lori A.
    Rha, Sun-young
    Kollmannsberger, Christian
    North, Scott
    Kanesvaran, Ravindran
    Rini, Brian I.
    Broom, Reuben
    Yamamoto, Haru
    Kaymakcalan, Marina D.
    Heng, Daniel Y. C.
    Choueiri, Toni K.
    CLINICAL GENITOURINARY CANCER, 2017, 15 (03) : 403 - 410
  • [48] Impact of tumor size on survival outcome in metastatic renal cell carcinoma patients (mRCC) treated with targeted therapy.
    Xie, Wanling
    DiNatale, Renzo
    Hakimi, A. Ari
    Donskov, Frede
    Porta, Camillo
    Reaume, M. Neil
    Basappa, Naveen S.
    Hansen, Aaron Richard
    Rini, Brian I.
    Beuselinck, Benoit
    Bjarnason, Georg A.
    Srinivas, Sandy
    Brugarolas, James
    Rha, Sun Young
    Wood, Lori
    Lalani, Aly-Khan A.
    Bosse, Dominick
    Duquette, Audrey
    Heng, Daniel Yick Chin
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [49] A new prognostic model of survival in second-line targeted therapy (TT) for metastatic renal cell carcinoma (mRCC).
    Derosa, Lisa
    Bayar, Mohamed Amine
    Albiges, Laurence
    Massard, Christophe
    Loriot, Yohann
    Fizazi, Karim
    Le Teuff, Gwenael
    Escudier, Bernard J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [50] Correlative analyses of serum biomarkers and clinical outcomes in the phase 2 study of lenvatinib, everolimus, and the combination, in patients with metastatic renal cell carcinoma following 1 VEGF-targeted therapy
    Glen, H.
    Hsieh, J.
    Michaelson, M. D.
    Kim, H. J.
    Sachdev, P.
    Kadowaki, T.
    Funahashi, Y.
    Larkin, J.
    Motzer, R.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S89 - S89
12345